The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.
Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.
In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.
Request a free sample copy or view report summary: Oligonucleotide Synthesis Market Report
Based on product & services, the service segment dominated the market with more than 37.0% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.
Grand View Research has segmented the global oligonucleotide synthesis market based on product & service, application, and region:
Oligonucleotide Synthesis Product & Service Outlook (Revenue, USD Billion, 2018 - 2030)
Oligonucleotides
DNA
Column-based
Array-based
RNA
By Technology
Column-based
Array-based
By Type
Short RNA Oligos (<65 nt)
Long RNA Oligos (>65 nt)
CRISPR (sgRNA)
Equipment/Synthesizer
Reagents
Services
DNA
Custom Oligo Synthesis Services
25 nmol
50 nmol
200 nmol
1000 nmol
10000 nmol
Modification Services
Purification Services
RNA
Custom Oligo Synthesis Services
25 nmol
100 nmol
1000 nmol
10000 nmol
Modification Services
Purification Services
Oligonucleotide Synthesis Application Outlook (Revenue, USD Billion, 2018 - 2030)
PCR Primers
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
PCR Assays & Panels
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Sequencing
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
DNA Microarrays
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Fluorescence In Situ Hybridization (FISH)
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Antisense Oligonucleotides
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Other Applications
Oligonucleotide Synthesis Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Oligonucleotide Synthesis Market
Thermo Fisher Scientific, Inc.
Merck KGaA
Danaher Corporation
Dharmacon Inc.
Agilent Technologies
Bio-synthesis
Kaneka Eurogentec S.A
LGC Biosearch Technologies
Biolegio
Twist Bioscience
"The quality of research they have done for us has been excellent..."